Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D, Inc.
This was a single-center, randomized, open-label, active-controlled, 2-period, 2-sequence, single dose-dose, crossover comparison of the ability of Albuterol BOI-HFA to produce bronchodilation relative to that produced by to albuterol MDI-HFA in at least 12 asthmatics with poor inhaler coordinating ability.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Asthma diagnosed ≥6 months prior and stable for 4 weeks prior to screening
Poor inhaler coordination as assessed at screening
Reversible bronchoconstriction (≥ 12% increase in FEV1)
You may not be if
Albuterol allergy
Investigational drug within 30 days
Injected corticosteroid within 6 weeks
Requires beta-blockers, MAO inhibitors, tricyclic antidepressants, long-acting beta-blockers, steroids other than those inhaled